Creo Medical Group PLC Director/PDMR Shareholding

RNS Number : 1953Q

Creo Medical Group PLC

16 December 2024

LEI: 213800H188ZDCWWXFA21

Creo Medical Group plc

("Creo" or the "Company")

Director/PDMR Share Dealings

The Company has been informed that on 13 December 2024 Kevin T. Crofton, Non-Executive Chairman, purchased Ordinary Shares in the Company at an average price of 17.015 pence per share as follows:

Director/PDMR Name	No. of Ordinary Shares Acquired	Resultant Shareholding post transaction	% of voting rights post transaction
Kevin T. Crofton	1,179,000	4,745,666	1.15%

This announcement contains inside information.

For further information please contact:

Creo Medical Group plc		www.creomedical.com
Richard Craven, Company Secretary		Via Walbrook PR

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)		+44 (0)20 7220 0500
Stephen Keys / Camilla Hume / George Lawson (NOMAD)
Michael Johnson (Sales)

Deutsche Numis (Joint Broker) Freddie Barnfield / Duncan Monteith / Euan Brown William Baunton (ECM)		+44 (0)20 7260 1000

Walbrook PR Ltd	Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Alice Woodings Philip Marriage	Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 Mob: +44 (0)7867 984 082

About Creo Medical

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com

A close-up of a device Description automatically generated

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Kevin T. Crofton
2	Reason for the notification
a)	Position/status	Non-Executive Chairman
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Creo Medical Group plc
b)	LEI	213800H188ZDCWWXFA21
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of £0.001 each
	Identification code	GB00BZ1BLL44
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volumes(s)	Price(s)	Volume(s)
		Average price of £0.17015	1,179,000
d)	Aggregated information
	Aggregated volume	1.179,000
	Price	Average price of £0.17015
e)	Date of the transaction	13 December 2024
f)	Place of the transaction	London Stock Exchange

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFFFELFVLELIS

Creo Medical (LSE:CREO)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024